PAC & Forth Episode 13:
Sam Chung
What good is innovation if patients can't get it?"
In this episode of PAC & Forth, we sit down with Sam Chung, Senior Vice President of Government Relations and External Affairs at California Life Sciences, which represents 1,300 organizations across the state’s biopharma, biotech, medical device, and research community.
Sam unpacks:
How prior authorization is driving real harm, with one in three patients facing adverse outcomes.
Why vertical integration of PBMs, insurers, and pharmacies is fueling cost and access problems.
The push behind SB 41 and broader PBM reform, and why rebate transparency matters.
The effort to eliminate prior auth for FDA-approved rare disease treatments, where delay can be catastrophic.
A clear view of where breakthrough treatments stall and what it would take to get them to patients faster.
If you’ve ever watched a patient wait for a treatment that’s already on the shelf, this episode is essential listening.
Tune in to hear why physicians and innovators have to push together.
More PAC & Forth Episodes
